Inflammatory Bowel Diseases and Biological Treatment in SARS-CoV-2 Era. Why Not?

Affiliations

Comment

Roberto Grassia et al. Inflamm Bowel Dis. 2020.

. 2020 Jun 18;26(7):e71.

doi: 10.1093/ibd/izaa110.

No abstract available

Keywords: COVID-19; SARS-CoV-2; biological treatment; inflammatory bowel diseases.

Comment on

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Zhou F, et al. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Lancet. 2020. PMID: 32171076 Free PMC article.

1. Zhou F, Yu T, Du R, et al. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. - PMC - PubMed
1. An P, Ji M, Ren H, et al. . Protection of 318 Inflammatory Bowel Disease Patients from the Outbreak and Rapid Spread of COVID-19 Infection in Wuhan, China. Rochester, NY: Preprints with the Lancet; 2020.
1. Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology. 2020. doi: 10.1053/j.gastro.2020.04.012. - DOI - PMC - PubMed
1. Norsa L, Indriolo A, Sansotta N, et al. . Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy. Gastroenterology. 2020. doi: 10.1053/j.gastro.2020.03.062. - DOI - PMC - PubMed
1. Monteleone G, Ardizzone S. Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? J Crohns Colitis. 2020. doi: 10.1093/ecco-jcc/jjaa061. - DOI - PMC - PubMed